Curated News
By: NewsRamp Editorial Staff
March 13, 2026

Sigyn Therapeutics Unveils CardioDialysis™ for Heart Disease, Eyes Merger Strategy

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Sigyn Therapeutics' CardioDialysis offers a competitive edge by targeting cardiovascular disease more effectively than drugs using existing dialysis infrastructure at 7,500 clinics.
  • Sigyn's CardioDialysis works by removing cholesterol-transporting lipoproteins and inflammatory molecules from blood using dialysis machines to reduce cardiovascular events and sepsis mortality.
  • Sigyn's therapies could save lives by addressing cardiovascular disease and sepsis, the world's leading causes of death, improving patient outcomes and reducing healthcare burdens.
  • Sigyn's CEO previously developed a TIME-recognized medical breakthrough and now targets traumatic brain injury with CardioDialysis while navigating Nasdaq listing challenges.

Impact - Why it Matters

This news matters because it addresses two of healthcare's most pressing challenges: cardiovascular disease and sepsis, which together account for millions of deaths globally annually. Sigyn's CardioDialysis™ represents a potential paradigm shift by leveraging existing dialysis infrastructure to treat heart disease more effectively than current drugs, potentially reducing heart attacks and strokes on a large scale. For patients, this could mean more accessible, non-pharmaceutical interventions for life-threatening conditions. The company's financial strategies, including a potential merger, highlight the real-world hurdles innovative biotech firms face in securing funding for breakthrough therapies, which directly impacts how quickly such treatments can reach the market. Investors and the medical community should watch closely, as success here could catalyze similar approaches in therapeutic device development.

Summary

Sigyn Therapeutics, Inc., a medical technology company trading on the OTCQB under the ticker SIGY, has issued a comprehensive shareholder update from its CEO, Jim Joyce. The update highlights the company's development of CardioDialysis™, a novel dialysis-like therapy designed to treat cardiovascular disease—the world's leading cause of death—by targeting cholesterol-transporting lipoproteins and inflammatory molecules. Unlike limited lipoprotein apheresis centers, CardioDialysis™ is engineered for use on existing dialysis machines, potentially expanding access significantly. The therapy also shows promise in preclinical studies for addressing sepsis, traumatic brain injury (TBI), and other inflammatory disorders, with the TBI indication being considered for a strategic transaction to leverage its value.

The core message from CEO Jim Joyce, who previously founded Aethlon Medical and led the development of the FDA-cleared Hemopurifier™, centers on Sigyn's therapeutic advancements and its current financial challenges. Joyce details the company's failed attempt to uplist to Nasdaq due to regulatory hurdles, describing a "catch-22" situation with the SEC and Nasdaq that forced the withdrawal of their registration statement. To navigate forward with reduced shareholder dilution, Sigyn is exploring strategies including the sale of certain assets and a potential merger with a Nasdaq-listed company at risk of not meeting minimum market value requirements. The update encourages stakeholders to follow industry colleagues at Spectral Medical, whose PMX device for sepsis is advancing through clinical studies.

Sigyn's pipeline extends beyond CardioDialysis™ to include cancer-focused therapies like ImmunePrep™, ChemoPrep™, and ChemoPure™, aimed at optimizing drug delivery and reducing chemotherapy toxicity. The company, with 2,330,042 shares outstanding as of March 11, 2026, emphasizes its mission to develop life-saving therapies despite its OTC trading status. For more details, readers can view the original release on www.newmediawire.com, and additional information is available at the company's website, www.SigynTherapeutics.com. This update underscores Sigyn's commitment to addressing critical unmet medical needs while navigating complex financial landscapes to advance its innovative medical devices.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sigyn Therapeutics Unveils CardioDialysis™ for Heart Disease, Eyes Merger Strategy

blockchain registration record for this content.